These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36639277)

  • 1. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients.
    Deveci B; Ateşoğlu EB; Bayrak E; Kublashvili G; Toptaş T; Saba R; Gülbaş Z
    Transplant Proc; 2023; 55(1):235-241. PubMed ID: 36639277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
    Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
    Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
    Liu H; Zou H; Shan D; Liu W; Huang W; Sui W; Deng S; Wang T; Lv R; Fu M; Xu Y; Yi S; An G; Zhao Y; Qiu L; Zou D
    Cancer Med; 2024 Jan; 13(2):e6965. PubMed ID: 38348996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.
    Wang R; Shangguan X; Zhu Z; Cong D; Bai Y; Zhang W
    Ann Hematol; 2024 Jul; 103(7):2455-2462. PubMed ID: 38809456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
    Gunes AK; Serin I; Demir I; Sarifakiogullari S; Durusoy SS; Akkurt DM; Ince I; Ozkan G; Cinli TA; Pehlivan M
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):201-207. PubMed ID: 33933474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients.
    Xiong YY; Wang J; Wang L; Chen JB; Liu L; Tang XQ; Wang X; Zhang HB
    Sci Rep; 2022 Aug; 12(1):14369. PubMed ID: 35999255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
    Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.